Anti-influenza viral composition containing bark or stem extract of alnus japonica

Abstract

The present invention relates to an antiviral composition comprising an Alnus japonica extract, more specifically, relates to a method for preparing high activated anti-influenza viral composition, which comprises an extract of the bark or stem of Alnus japonica , and an anti-influenza viral composition comprising the extract. An extract of the bark or stem of Alnus japonica according to the present invention has low toxicity to normal cells, while having an excellent antiviral effect even when administered at low concentration and thus the composition comprising the Alnus japonica extract can be used effectively in preventing and treating influenza viral infection.

1 . A method for preparing an extract of the bark or stem of  Alnus japonica , which has an anti-influenza viral activity, the method comprising the steps of:
 (a) extracting the bark or stem of Korean indigenous  Alnus japonica  with 80˜100% ethanol at 30˜80° C.; and   (b) recovering the resulting extraction solution at the same temperature by vacuum concentrating and drying.   
     
     
         2 . A food composition for preventing or improving influenza viral infection, which comprises an extract of the bark or stem of  Alnus japonica , prepared by the method of  claim 1 , and a sitologically acceptable supplemental additive. 
     
     
         3 . The composition according to  claim 2 , wherein said influenza virus is selected from the group consisting of human influenza virus, swine influenza virus, equine influenza virus, and avian influenza virus. 
     
     
         4 . The composition according to  claim 3 , wherein said avian influenza virus is KBNP-0028 (KCTC 10866BP). 
     
     
         5 . A pharmaceutical composition for preventing or treating influenza viral infection, which comprises an extract of the bark or stem of  Alnus japonica , prepared by the method of  claim 1 , as an active ingredient. 
     
     
         6 . The pharmaceutical composition according to  claim 5 , wherein said influenza virus is selected from the group consisting of human influenza virus, swine influenza virus, equine influenza virus, and avian influenza virus. 
     
     
         7 . The pharmaceutical composition according to  claim 6 , wherein said avian influenza virus is KBNP-0028 (KCTC 10866BP).